Product Information

CAS No.	2222941-37-7
Product Name	Inobrodib

Associated Conditions

neoplasm·prostate cancer

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.

Cancer cell • Vol. 41, Issue 12 • 2023

PMID: 37995682 DOI: 10.1016/j.ccell.2023.11.001

Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.

Bioorganic chemistry • Vol. 124 • 2022

PMID: 35439627 DOI: 10.1016/j.bioorg.2022.105803

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Journal of medicinal chemistry • Vol. 65, Issue 1 • 2022

PMID: 34962793 DOI: 10.1021/acs.jmedchem.1c01864

Targeting the p300/CBP Axis in Lethal Prostate Cancer.

Cancer discovery • Vol. 11, Issue 5 • 2021

PMID: 33431496 PMC: PMC8102310 DOI: 10.1158/2159-8290.CD-20-0751

Inobrodib

CAS No.	2222941-37-7
MDL No.	N/A
MF	C₃₀H₃₂F₂N₄O₃
MW	534.60
InChI Key	SKDNDJWEBPQKCS-RIQBOWGZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	2222941-37-7
Product Name	Inobrodib

Associated Conditions

neoplasm·prostate cancer

* The information provided here is compiled from public sources and is for reference only.

Inobrodib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Inobrodib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Documentation

Inobrodib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Related Articles

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.

Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Targeting the p300/CBP Axis in Lethal Prostate Cancer.

Similar Products

Brigimadlin

GLP-1 receptor agonist 14

DBCO-|A-Glu-PEG12-Exatecan

Navelbine ditartrate (TN)

Vinorelbine

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-

Inobrodib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Related Articles

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.

Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Targeting the p300/CBP Axis in Lethal Prostate Cancer.

Similar Products

Brigimadlin

GLP-1 receptor agonist 14

DBCO-|A-Glu-PEG12-Exatecan

Navelbine ditartrate (TN)

Vinorelbine

Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-

Documentation